Denovicon’s platform is broadly applicable across therapeutic areas and biological targets. Presently, our internal R&D efforts prioritize small-molecule therapeutics for various targets within the DNA damage response (DDR) pathways and immuno-oncology. In particular, we are advancing best-in-class and first-in-class compounds that selectively inhibit PARP1, PARP2, and PARP7, addressing unmet needs in oncology, immunology, neuroscience, and cardiovascular disease.